Search hospitals
>
Iowa
>
Des Moines
Mercy Medical Center - Des Moines
Claim this profile
Des Moines, Iowa 50314
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Ovarian Cancer
Conducts research for Breast cancer
388 reported clinical trials
6 medical researchers
Summary
Mercy Medical Center - Des Moines is a medical facility located in Des Moines, Iowa. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Ovarian Cancer, Breast cancer and other specialties. Mercy Medical Center - Des Moines is involved with conducting 388 clinical trials across 520 conditions. There are 6 research doctors associated with this hospital, such as Richard L. Deming, Mehmet S. Copur, Atul Chawla, MD, and Robert Hoyt, MD.
Area of expertise
Breast Cancer
Mercy Medical Center - Des Moines has run 77 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Mercy Medical Center - Des Moines has run 71 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Richard L. Deming
Mercy Medical Center - Des Moines
7 years of reported clinical research
Mehmet S. Copur
Bethesda North Hospital
13 years of reported clinical research
Atul Chawla, MD
Mercy Hospital Medical Center
8 years of reported clinical research
Robert Hoyt, MD
Iowa Heart Center
7 years of reported clinical research
Clinical Trials running at Mercy Medical Center - Des Moines
Bladder Cancer
Lung Cancer
Breast Cancer
Cancer
Breast cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Multiple Myeloma
Small Cell Lung Cancer
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting
2 awards
Phase 3
Gemcitabine + Cisplatin
for Bladder Cancer
This phase II trial studies how well gemcitabine hydrochloride and cisplatin work in treating participants with invasive bladder urothelial cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Recruiting
1 award
Phase 2
Blood Test and Immunotherapy
for Bladder Cancer
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.
Recruiting
1 award
Phase 2 & 3
10 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Mercy Medical Center - Des Moines?
Mercy Medical Center - Des Moines is a medical facility located in Des Moines, Iowa. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Ovarian Cancer, Breast cancer and other specialties. Mercy Medical Center - Des Moines is involved with conducting 388 clinical trials across 520 conditions. There are 6 research doctors associated with this hospital, such as Richard L. Deming, Mehmet S. Copur, Atul Chawla, MD, and Robert Hoyt, MD.
Where is Mercy Medical Center - Des Moines located?
MercyOne Des Moines Medical Center is located at 1111 6th Ave, Des Moines, IA 50314.
Who should I call to ask about financial aid or insurance network?
**Financial Assistance and Insurance Information for Mercy Medical Center - Des Moines** - **Mercy Health Financial Assistance Policy**: Offers financial aid to eligible patients based on income and financial resources. Information and applications are available on their website. - **MercyOne Financial Assistance Program**: Provides financial assistance for medical bills to eligible uninsured or underinsured patients. Application and policy details are on their website. - **MercyOne Billing & Finances**: For billing and financial inquiries, contact MercyOne at the following numbers: Clinic - 888-515-7155, Hospital - 734-343-3065, Iowa Heart - 515-633-3600, Lab - 844-405-9080. Financial counselors are available to discuss individual needs and payment arrangements. - **MercyOne Insurance**: At registration, provide your insurance information. MercyOne will file your claim and, if possible, inform you of the approximate amount owed and arrange for payment. - **MercyOne Discounted Charges**: Hospital patients without insurance who meet income guidelines may receive a discount off total billed charges. An application is required.
What insurance does Mercy Medical Center - Des Moines accept?
Mercy Medical Center - Des Moines accepts a broad spectrum of insurance plans, including Medicare, Medicaid, and commercial carriers like Aetna, Humana, United Healthcare, and Wellmark (BCBS). Patients are encouraged to confirm coverage and any restrictions with their insurance provider prior to scheduling visits. Note that non-participating insurance plans may lead to the patient being responsible for total billed charges.
What awards or recognition has Mercy Medical Center - Des Moines received?
Mercy Medical Center - Des Moines is an accredited cancer center by the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), highlighting its quality cancer care. It has been named a Best Regional Hospital for Des Moines and central Iowa by U.S. News & World Report. Additionally, it has earned the Blue Distinction Center Plus (+) designation for cardiac care from Blue Cross Blue Shield.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.